Research on the clinical utility and benefits of whole genome analysis in patients of refractory cancer

JRCT ID: jRCT1040240090

Registered date:26/09/2024

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Refractory cancers (including rare cancers, AYA cancers, and cancers of unknown primary origin)
• Date of first enrollment: 01/08/2024
• Target sample size: 250
• Study type: Observational

Outcome(s)

• Primary Outcome: Proportion of patients who achieved treatment based on the test, and proportion of patients who were successful in the test

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Include criteria: Patients with refractory cancers for whom tissue samples and peripheral blood samples collected and frozen through surgeries or examinations conducted at Nagoya University Hospital will be available and can be submitted for genome analysis by March 31, 2025, following approval. Alternatively, patients with refractory cancers for whom existing tissue samples and peripheral blood samples that were collected and frozen through past surgeries or examinations conducted at Nagoya University Hospital are available, and survival can be confirmed, and contact can be made by March 31, 2025, and the samples can be submitted for genome analysis.

Exclude criteria

Cases where it is difficult to obtain suitable tissue samples or peripheral blood samples for examination.
Cases deemed unsuitable by the principal investigator or sub-investigators.
Cases where consent for the study could not be obtained.

Related Information

• Primary Sponsor: Yuichi Ando